Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Real-time Estimate Tradegate  -  03:34:41 2023-03-24 pm EDT
55.54 EUR   -0.72%
12:20pBayer's pharma chief hopes EU takes time to improve drug rules reform
RE
11:55aBayer to Shift Drug Research Focus Away from Women's Health
MT
11:32aVividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer investor calls for swift replacement of CEO: newspaper

01/28/2023 | 06:34am EDT
FILE PHOTO: Bayer CEO Werner Baumann addresses the company's annual results news conference

FRANKFURT (Reuters) - Bayer investor Deka has called for CEO Werner Baumann to be replaced ahead of his scheduled departure, adding to mounting pressure on the German drugmaker.

"Bayer needs a new strategic positioning, which cannot be credibly accomplished under Werner Baumann," Ingo Speich, head of sustainability and corporate governance at Deka, told the Frankfurter Allgemeine Sonntagszeitung (FAS) newspaper in remarks published on Saturday.

The mutual funds firm is among Bayer's 20 largest shareholders.

"There is a window of opportunity for Chairman Norbert Winkeljohann to act before the annual general meeting at the end of April. He has to seize that opportunity, otherwise the pressure on him will increase as well," Speich added.

He said a successor would have to come from outside the company.

"Generally speaking we are always open to a constructive dialogue with our stakeholders," a Bayer spokesperson said, declining to comment specifically on the interview.

Despite recent improvements in the company's agriculture business and drug development prospects, Bayer shares have been weighed down by litigation over glyphosate-based herbicide Roundup and over environmental pollution related to chemicals known as PCBs.

The legal claims are legacy issues from its takeover of Monsanto for more than $60 billion in 2018.

Baumann, who engineered the troubled Monsanto deal, was given a new contract in 2020 that runs until 2024 and said at the time he would leave the company when that term expires.

A week ago mutual funds group Union Investment criticised Bayer's chair for a lack of engagement, such as exploring a spin-off of the company's consumer health division.

Bayer is also facing demands from activist investor Bluebell Capital Partners to break up the company, including selling off its consumer health unit and later a separation of its pharmaceuticals and agricultural businesses.

Another activist investment fund, hedge fund veteran Jeffrey Ubben's Inclusive Capital Partners, said this month it had also acquired a stake in Bayer.

(Reporting by Ludwig Burger; editing by Jason Neely)


ę Reuters 2023
All news about BAYER AG
12:20pBayer's pharma chief hopes EU takes time to improve drug rules reform
RE
11:55aBayer to Shift Drug Research Focus Away from Women's Health
MT
11:32aVividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer
AQ
03/23Bayer, Orion Expand Development Program for Prostate Cancer Drug
MT
03/23BAYER AG : Berenberg keeps its Buy rating
MD
03/22Syngenta 4Q profit falls as raw material prices increase
RE
03/22Syngenta 4Q profit falls as raw material prices increase
RE
03/20Swiss Banking Rescue Deal, Cooling PPI Push German Shares Higher
MT
03/20Orion, Bayer's Prostrate Cancer Treatment Darolutamide Wins Chinese Regulatory Nod
MT
03/14Bayer : BlueRock Therapeutics to incorporate wearable and invisible contactless digital he..
PU
More news
Analyst Recommendations on BAYER AG
More recommendations
Financials
Sales 2023 50 688 M 54 527 M 54 527 M
Net income 2023 4 496 M 4 837 M 4 837 M
Net Debt 2023 31 865 M 34 279 M 34 279 M
P/E ratio 2023 12,1x
Yield 2023 4,43%
Capitalization 54 574 M 58 707 M 58 707 M
EV / Sales 2023 1,71x
EV / Sales 2024 1,61x
Nbr of Employees 97 922
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 55,94 €
Average target price 74,90 €
Spread / Average Target 33,9%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG15.76%59 859
JOHNSON & JOHNSON-14.45%394 993
NOVO NORDISK A/S10.32%340 383
ELI LILLY AND COMPANY-9.08%300 007
ABBVIE INC.-3.90%273 971
MERCK & CO., INC.-6.06%264 597
Stock markets for all
100% Free Registration
fermer